Dermatology · North Carolina
Dermatology and skin studies in North Carolina
22 studies have at least one recruiting site in North Carolina. Skin studies test treatments for conditions such as psoriasis, eczema, acne, alopecia, vitiligo and hidradenitis suppurativa, from creams to tablets and injections.
22 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Sagimet Biosciences Inc.
- Location
- Wilmington, NC + 17 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics, Inc.
- Location
- Wilmington, NC + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- Wilmington, NC + 18 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda
- Location
- Hickory, NC + 45 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Chapel Hill, NC + 16 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- Charlotte, NC + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Cary, NC + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Huntersville, NC + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Chapel Hill, NC + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Janssen Research & Development, LLC
- Location
- Chapel Hill, NC
- Eligibility basics
- Ages 18+ · Women only
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Janssen Research & Development, LLC
- Location
- Charlotte, NC + 20 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics
- Location
- Wilmington, NC + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
Janssen Research & Development, LLC
- Location
- Charlotte, NC + 17 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Vanda Pharmaceuticals
- Location
- Wilmington, NC + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
UCB Biopharma SRL
- Location
- Chapel Hill, NC + 5 other US sites
- Eligibility basics
- Ages 18+ · Women only
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Charlotte, NC + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Cary, NC + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
AbbVie
- Location
- Chapel Hill, NC + 11 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 1/Phase 2
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur, a Sanofi Company
- Location
- Wilmington, NC + 78 other US sites
- Eligibility basics
- Ages 18–45
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Inmagene LLC
- Location
- Charlotte, NC + 15 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Cary, NC + 53 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
AbbVie
- Location
- Wilmington, NC + 9 other US sites
- Eligibility basics
- Ages 22+
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Do I need a diagnosis to join a skin study?
Usually yes, and the site will confirm it at screening. Some studies also recruit people without the condition as a comparison group.